A panelist discusses how four FDA-approved agents treat steroid-refractory cGVHD, including ibrutinib (65% response rate), ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response ...

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and ...

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem ...

In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual Meeting.

Alicia Morgans, MD, MPH, discusses the phase 3 ARASTEP trial evaluating darolutamide in patients at high risk of biochemical recurrence of prostate cancer.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.